A similar KRAS electromobility shift, indicative of covalent compound binding, was observed following AZ’1569 treatment across the colorectal cancer panel, suggesting that differential sensitivity was unlikely due to differences in target engagement (25). Here, KRAS is linked to colorectal cancer.